BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 10559598)

  • 1. Pemphigus erythematosus: detection of anti-desmoglein-1 antibodies by ELISA.
    Gomi H; Kawada A; Amagai M; Matsuo I
    Dermatology; 1999; 199(2):188-9. PubMed ID: 10559598
    [No Abstract]   [Full Text] [Related]  

  • 2. Limitations in enzyme-linked immunosorbent assays for antibodies against desmogleins 1 and 3 in patients with pemphigus.
    Bystryn JC; Akman A; Jiao D
    Arch Dermatol; 2002 Sep; 138(9):1252-3. PubMed ID: 12224997
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of pemphigus vulgaris in a patient with pemphigus foliaceus: antidesmoglein antibody profile shift confirmed by enzyme-linked immunosorbent assay.
    Ishii K; Amagai M; Ohata Y; Shimizu H; Hashimoto T; Ohya K; Nishikawa T
    J Am Acad Dermatol; 2000 May; 42(5 Pt 2):859-61. PubMed ID: 10767686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An experience for ELISA for desmoglein 1, suggesting a possible diagnostic help to determine the initial therapy for pemphigus foliaceus.
    Aoyama Y; Tsujimura Y; Funabashi M; Sato M; Kamiya H; Kitajima Y
    Eur J Dermatol; 2000; 10(1):18-21. PubMed ID: 10694292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemphigus Herpetiformis With Autoantibodies to Desmoglein 1 and 3.
    Galvañ-Pérez Del Pulgar JI; Tercedor-Sánchez J; Jiménez-Gallo D; Linares-Barrios M
    Actas Dermosifiliogr; 2016 Nov; 107(9):785-786. PubMed ID: 27340117
    [No Abstract]   [Full Text] [Related]  

  • 6. 230-kDa and 190-kDa proteins in addition to desmoglein 1 as immunological targets in a subset of pemphigus foliaceus with a combined cell-surface and basement membrane zone immune staining pattern.
    Karlhofer FM; Hashimoto T; Slupetzky K; Kiss M; Liu Y; Amagai M; Pieczkowski F; Foedinger D; Kirnbauer R; Stingl G
    Exp Dermatol; 2003 Oct; 12(5):646-54. PubMed ID: 14705806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG/IgA pemphigus with IgG and IgA antidesmoglein 1 antibodies detected by enzyme-linked immunosorbent assay.
    Oiso N; Yamashita C; Yoshioka K; Amagai M; Komai A; Nagata Y; Hashimoto T; Ishii M
    Br J Dermatol; 2002 Nov; 147(5):1012-7. PubMed ID: 12410717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1.
    Brenner S; Ruocco V
    J Am Acad Dermatol; 1998 Jul; 39(1):137-8. PubMed ID: 9674417
    [No Abstract]   [Full Text] [Related]  

  • 9. Desmoglein ELISAs: a novel diagnostic tool for pemphigus.
    Nishikawa T
    Arch Dermatol; 1999 Feb; 135(2):195-6. PubMed ID: 10052407
    [No Abstract]   [Full Text] [Related]  

  • 10. Enzyme-linked immunosorbent assay as a helpful diagnostic tool for pemphigus erythematosus with equivocal histologic and immunofluorescent findings.
    Desai A; Harris J; Motaparthi K
    Dermatol Online J; 2018 Aug; 24(8):. PubMed ID: 30677852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DSG 3 and DSG 1-ELISA as a specific diagnostic tool in oral bullous diseases.
    Sistig S; Lukac J; Vucicevic-Boras V; Malenica B
    Eur J Med Res; 2002 Apr; 7(4):181-2. PubMed ID: 12017158
    [No Abstract]   [Full Text] [Related]  

  • 12. Neonatal pemphigus vulgaris: IgG4 autoantibodies to desmoglein 3 induce skin blisters in newborns.
    Parlowsky T; Welzel J; Amagai M; Zillikens D; Wygold T
    J Am Acad Dermatol; 2003 Apr; 48(4):623-5. PubMed ID: 12664033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A sensitive and restricted enzyme-linked immunosorbent assay for detecting a heterogeneous antibody population in serum from people suffering from a new variant of endemic pemphigus.
    Abréu-Vélez AM; Yepes MM; Patiño PJ; Bollag WB; Montoya F
    Arch Dermatol Res; 2004 Mar; 295(10):434-41. PubMed ID: 14730452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Desmoglein1 and BP 180 ELISA indexes correlating with disease activity in a patient with coexisting pemphigus foliaceus and bullous pemphigoid.
    Ando S; Sato-Matsumura KC; Kasai M; Nemoto-Hasebe I; Hoshina D; Ohyama B; Hashimoto T; Shimuzu H
    Clin Exp Dermatol; 2009 Dec; 34(8):e995-6. PubMed ID: 20055881
    [No Abstract]   [Full Text] [Related]  

  • 15. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of D-penicillamine in drug-induced pemphigus foliaceus.
    Nagao K; Tanikawa A; Yamamoto N; Amagai M
    Clin Exp Dermatol; 2005 Jan; 30(1):43-5. PubMed ID: 15663502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus.
    Hashimoto T; Komai A; Futei Y; Nishikawa T; Amagai M
    Arch Dermatol; 2001 Jun; 137(6):735-8. PubMed ID: 11405762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of antibodies against desmoglein 1 in endemic pemphigus foliaceus in Brazil. Cooperative Group on Fogo Selvagem Research.
    Warren SJ; Lin MS; Giudice GJ; Hoffmann RG; Hans-Filho G; Aoki V; Rivitti EA; Santos V; Diaz LA
    N Engl J Med; 2000 Jul; 343(1):23-30. PubMed ID: 10882765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytokine pattern in blister fluid and sera of patients with pemphigus.
    Baroni A; Perfetto B; Ruocco E; Greco R; Criscuolo D; Ruocco V
    Dermatology; 2002; 205(2):116-21. PubMed ID: 12218224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of pemphigus autoantibodies by IIF and ELISA tests in patients with pemphigus vulgaris and foliaceus and in healthy relatives.
    Torzecka JD; Narbutt J; Sysa-Jedrzejowska A; Waszczykowska E; Lukamowicz J; Pas HH
    Med Sci Monit; 2003 Dec; 9(12):CR528-33. PubMed ID: 14646976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris.
    Sami N; Bhol KC; Ahmed RA
    Eur J Dermatol; 2003; 13(4):377-81. PubMed ID: 12948919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.